Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023.
Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014 (PAMA). ADLT status is reserved for innovative tests with Medicare coverage that provide new clinical diagnostic information that cannot be obtained from any other test or combination of tests. The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649.
Also Read: Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich
“Receiving ADLT status is a major milestone for Biodesix and confirms the clinical value and unique nature of the Nodify CDT test,” says Scott Hutton, President and CEO of Biodesix. “We are committed to working closely with CMS and commercial payers to ensure that patients and physicians have access to all tests in the Biodesix portfolio that aid in the diagnosis and treatment of lung cancer.”
The Nodify CDT test is used in combination with the Nodify XL2 test, previously awarded ADLT status on May 17, 2019, in Nodify Lung® Nodule Risk Assessment Testing. These tests are designed to help physicians assess the risk of malignancy of pulmonary nodules to identify and prioritize high risk nodules for intervention while avoiding unnecessary invasive procedures on benign nodules.
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung nodule risk assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action.
SOURCE: Businesswire